%0 Journal Article
%T Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma
%A Ayako Hirai
%A Fumihiro Tanaka
%A Kazue Yoneda
%A Koji Kuroda
%A Masaru Takenaka
%A Masataka Mori
%A Masatoshi Kanayama
%A Naoko Imanishi
%A Soichi Oka
%A Taiji Kuwata
%A Takashi Ohnaga
%A Yasuhiro Chikaishi
%A Yoshinobu Ichiki
%J Archive of "Cancer Science".
%D 2019
%R 10.1111/cas.13895
%X Detection of rare tumor cells circulating in the blood (CTCs) presents technical challenges. CellSearch, the only approved system for clinical use, fails to capture epithelial cell adhesion molecule©\negative CTCs such as malignant pleural mesothelioma (MPM). We have developed a novel microfluidic device (CTC©\chip) in which any Ab to capture CTCs is conjugated. The CTC©\chip was coated with an Ab against podoplanin that is abundantly expressed on MPM. Circulating tumor cell©\detection performance was evaluated in experimental models in which MPM cells were spiked in blood sampled from a healthy volunteer and in clinical samples drawn from MPM patients. The CTC©\chip showed superior CTC©\detection performance over CellSearch in experimental models (sensitivity, 63.3%©\64.5% vs 0%©\1.1%; P < .001) and in clinical samples (CTC©\positivity, 68.8% vs 6.3%; P < .001). A receiver operating characteristic (ROC) analysis showed that the CTC test provided a significant diagnostic performance in discrimination of unresectable disease from resectable disease (area under the ROC curve, 0.851; P = .003). The higher CTC count (¡Ý2 cells/mL) was significantly associated with a poor prognosis (P = .030). The novel CTC©\chip enabled sensitive detection of CTCs, which provided significant diagnostic and prognostic information in MPM
%K circulating tumor cell
%K CTC©\chip
%K mesothelioma
%K podoplanin
%K prognosis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361567/